Granisetron
Serotonin-3 Receptor Antagonist — ALIMENTARY TRACT AND METABOLISM
Also known as: BRL-43694, granisetron HCl, granisetron hydrochloride, granisetron monohydrochloride, kevatril, kytril, sancuso
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Granisetron is an ofp drug in the Serotonin-3 Receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 1993. Its mechanism of action is classified as Serotonin 3 Receptor Antagonists. DrugCentral lists 9 molecular targets, including Htr3a|Htr3b, HTR3B and HTR3A. Recorded indications include Chemotherapy-induced nausea and vomiting, Post-Operative Nausea and Vomiting, Prevention of Post-Operative Nausea and Vomiting and Prevention of Radiation-Induced Nausea and Vomiting.
- Approval status: ofp (first approved 1993 by the FDA).
- Drug class: Serotonin-3 Receptor Antagonist.
- Mechanism of action: Serotonin 3 Receptor Antagonists.
- Molecular targets: Htr3a|Htr3b, HTR3B, HTR3A and HTR3A (9 listed in DrugCentral).
- Indications: Chemotherapy-induced nausea and vomiting, Post-Operative Nausea and Vomiting, Prevention of Post-Operative Nausea and Vomiting and Prevention of Radiation-Induced Nausea and Vomiting.
- ATC code: A04AA02 (Serotonin (5HT3) antagonists).
- Molecular formula: C18H24N4O; molecular weight 312.42 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (4)
- Chemotherapy-induced nausea and vomiting
- Post-Operative Nausea and Vomiting
- Prevention of Post-Operative Nausea and Vomiting
- Prevention of Radiation-Induced Nausea and Vomiting
Off-label uses (1)
- Prolonged-Severe Nausea and Vomiting
Contraindications (6)
- Conduction disorder of the heart
- Congenital long QT syndrome
- Doxorubicin Induced Cardiomyopathy
- Hypokalemia
- Hypomagnesemia
- Prolonged QT interval
Mechanism & targets
| Mechanism of action (MoA) | Serotonin 3 Receptor Antagonists |
|---|---|
| Established pharmacologic class | Serotonin-3 Receptor Antagonist |
Molecular targets (9)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Serotonin 3 (5-HT3) receptor | Htr3a|Htr3b | unknown | Ki 9.46 |
| 5-hydroxytryptamine receptor 3B | HTR3B | unknown | Ki 8.80 |
| 5-hydroxytryptamine receptor 3A | HTR3A | antagonist | Ki 8.70 |
| 5-hydroxytryptamine receptor 3A | HTR3A | unknown | Ki 8.40 |
| Potassium voltage-gated channel subfamily H member 2 | KCNH2 | unknown | IC50 5.43 |
| Solute carrier family 22 member 2 | SLC22A2 | unknown | IC50 5.37 |
| Multidrug and toxin extrusion protein 1 | SLC47A1 | unknown | IC50 5.30 |
| Neuronal acetylcholine receptor; alpha4/beta2 | CHRNB2|CHRNA4 | unknown | Ki 4.42 |
| Neuronal acetylcholine receptor subunit alpha-3 | CHRNA3 | unknown | Ki 4.17 |
Regulatory approvals (3)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2022-02-25 | PMDA | — | Taiyo Pharma Co Ltd | |
| 2012-04-20 | EMA | — | Kyowa Kirin Holdings B.V. | |
| 1993-12-29 | FDA | — | ROCHE |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A04AA02 | ALIMENTARY TRACT AND METABOLISM › ANTIEMETICS AND ANTINAUSEANTS › ANTIEMETICS AND ANTINAUSEANTS › Serotonin (5HT3) antagonists |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Febrile neutropenia | 1174.1 |
| Product adhesion issue | 697.4 |
| Nausea | 444.3 |
| Neutropenia | 335.3 |
| Neutrophil count decreased | 321.0 |
| Death | 271.3 |
| Drug ineffective | 267.7 |
| Anaemia | 248.9 |
| Pyrexia | 244.5 |
| Platelet count decreased | 225.2 |
| Vomiting | 219.0 |
| Leukopenia | 211.3 |
Chemical structure
| Molecular formula | C18H24N4O |
|---|---|
| Molecular weight | 312.42 g/mol |
| CAS number | 109889-09-0 |
| InChIKey | MFWNKCLOYSRHCJ-BTTYYORXSA-N |
| PubChem CID | 5284566 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Granisetron used for?
DrugCentral lists the following indications for Granisetron: Chemotherapy-induced nausea and vomiting, Post-Operative Nausea and Vomiting, Prevention of Post-Operative Nausea and Vomiting and Prevention of Radiation-Induced Nausea and Vomiting.
How does Granisetron work?
Granisetron is classified as Serotonin 3 Receptor Antagonists; its molecular targets in DrugCentral include Htr3a|Htr3b, HTR3B, HTR3A (antagonist) and HTR3A.
When was Granisetron first approved?
Granisetron was first approved by the FDA in 1993.
What drug class does Granisetron belong to?
Granisetron is in the Serotonin-3 Receptor Antagonist class.
What is the chemical formula of Granisetron?
Granisetron has the molecular formula C18H24N4O and a molecular weight of 312.42 g/mol.
Browse: all drugs starting with G · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1329 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1237080 — compound record and bioactivity
- PubChem CID 5284566 — chemical identifiers
- DrugBank DB00889 — drug record
- FDA UNII WZG3J2MCOL — substance identity
- DailyMed: FDA labels for Granisetron — current prescribing information (label search)
- UniProt O95264 (HTR3B) — target protein
- UniProt P46098 (HTR3A) — target protein
- UniProt Q12809 (KCNH2) — target protein
- UniProt O15244 (SLC22A2) — target protein
- UniProt Q96FL8 (SLC47A1) — target protein
- UniProt P32297 (CHRNA3) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.